Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Baars

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
The Netherlands Journal of Medicine|January 1, 1986
Post-transfusion purpuraJ W Baars, J D Gökemeijer, L Wijnja, et al.
The Netherlands Journal of Medicine|March 25, 2014
Cerebrovascular events during nilotinib treatmentN G L Jager, F E Stuurman, J W Baars, et al.
British Journal of Cancer|June 12, 2003
Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experienceJ G Schrama, M J Holtkamp, J W Baars, et al.
Human Antibodies|June 18, 2010
Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignanciesL Tran, J W Baars, L Aarden, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2003
Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase geneA B P van Kuilenburg, J W Baars, R Meinsma, et al.
Anticancer Research|August 21, 2003
Palliative chemotherapy after failure of high-dose chemotherapy in breast cancer--toxicity and efficacyJ G Schrama, M M de Boer, J W Baars, et al.
British Journal of Cancer|October 1, 1992
Lobular panniculitis after subcutaneous administration of interleukin-2 (IL-2), and its exacerbation during intravenous therapy with IL-2J W Baars, J L Coenen, J Wagstaff, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 10, 2012
Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesionL Tran, A D R Huitema, W V Vogel, et al.
Leukemia|July 30, 2003
Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacyL E van der Kolk, A J Grillo-López, J W Baars, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 1995
Therapy with interleukin-2 induces the systemic release of phospholipase-A2G J Wolbink, C Schalkwijk, J W Baars, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
The Netherlands Journal of Medicine|January 1, 1986
Post-transfusion purpuraJ W Baars, J D Gökemeijer, L Wijnja, et al.
The Netherlands Journal of Medicine|March 25, 2014
Cerebrovascular events during nilotinib treatmentN G L Jager, F E Stuurman, J W Baars, et al.
British Journal of Cancer|June 12, 2003
Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experienceJ G Schrama, M J Holtkamp, J W Baars, et al.
Human Antibodies|June 18, 2010
Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignanciesL Tran, J W Baars, L Aarden, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2003
Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase geneA B P van Kuilenburg, J W Baars, R Meinsma, et al.
Anticancer Research|August 21, 2003
Palliative chemotherapy after failure of high-dose chemotherapy in breast cancer--toxicity and efficacyJ G Schrama, M M de Boer, J W Baars, et al.
British Journal of Cancer|October 1, 1992
Lobular panniculitis after subcutaneous administration of interleukin-2 (IL-2), and its exacerbation during intravenous therapy with IL-2J W Baars, J L Coenen, J Wagstaff, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 10, 2012
Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesionL Tran, A D R Huitema, W V Vogel, et al.
Leukemia|July 30, 2003
Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacyL E van der Kolk, A J Grillo-López, J W Baars, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 1995
Therapy with interleukin-2 induces the systemic release of phospholipase-A2G J Wolbink, C Schalkwijk, J W Baars, et al.
Pageof 6